DNA topoisomerase II Inhibitors
2 drugsAbout DNA topoisomerase II
DNA topoisomerase II (topo II) is an enzyme essential for managing DNA topology within cells. It untangles DNA, relieving torsional stress during replication, transcription, and chromosome segregation by cutting and re-ligating DNA strands.
Topo II's role in cell division makes it a target for anti-cancer therapies, though no direct genetic evidence currently links topo II mutations to specific diseases. Its involvement in cell proliferation makes it a logical target for disrupting cancer cell growth.
Two FDA-approved drugs target DNA topoisomerase II: VALRUBICIN (Hikma) and VALSTAR PRESERVATIVE FREE (ENDO OPERATIONS). Both drugs are small molecules and are used in 'other' therapeutic areas.
Top DNA topoisomerase II Drugs
The competitive landscape includes Hikma and ENDO OPERATIONS, each with an approved drug.
Low market concentration suggests relatively low barriers to entry for new competitors.
DNA topoisomerase II Drug Modality Landscape
Modalities
Routes of Administration
DNA topoisomerase II is druggable by small molecules, though no oral formulations are currently approved.
Explore opportunities for novel modalities like antibodies or PROTACs to differentiate from existing therapies.
DNA topoisomerase II Clinical Trials 1 trial
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on DNA topoisomerase II. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
DNA topoisomerase II Drug Approval Timeline (1998 - 2019)
The first drug was approved in 1998, and the most recent in 2019, spanning 22 years.
The approval timeline indicates a potentially mature market with limited recent innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 1 (0 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on DNA topoisomerase II. A trial counts if an approved drug acting on DNA topoisomerase II is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.